HAE Stock Analysis — Haemonetics Corporation
Sector: Healthcare
AI Verdict
At 19.5x forward earnings with triple-digit EPS growth expected, this is cheap for the growth on offer if Haemonetics' hospital integration moat holds up.
Competitive Moat
Haemonetics specializes in blood management solutions for hospitals and blood centers, with a defensible moat built on proprietary apheresis technology and deep integration into hospital workflows. Switching costs and regulatory hurdles protect its installed base from new entrants.
Summary
A sharp expected earnings rebound is driving a steep drop in forward P/E for this blood management specialist.
Where It Stands
HAE trades at 19.5x next year's earnings, a discount to the healthcare sector median of 22x, with analysts forecasting a 146.7% jump in EPS and trailing P/E still high at 48.0x.
Key Metrics
- Trailing P/E: 48.0x
- Forward P/E: 19.5x
- PEG Ratio: 0.33
- Earnings Growth: +1.5%
- Revenue Growth: +0.0%
- 52-Week High: $109.57
- 52-Week Low: $47.32
Analyst Consensus
11 Buy · 4 Hold · 0 Sell (15 analysts)
Bull Case
Forward EPS growth of 146.7% means the stock is cheap for the growth you're getting at 19.5x forward earnings.
Bear Case
If the P/E reverts to the sector median of 22x but growth disappoints, the stock could see a sharp multiple contraction from its current 48.0x trailing P/E.
Catalyst to Watch
Quarterly earnings delivery is critical — if the 146.7% EPS growth fails to materialize, the valuation case evaporates.